AgingResearch.NewsJoin free

Repare Therapeutics

CompanyCanada

Repare Therapeutics develops one asset, in phase 1 (camonsertib in advanced solid tumor). Mostly small molecule; based in Canada.

1
Asset
Furthest stage
Phase 1
Raised
$82.5M
3
Trials
0
Signals

Pipeline

1

  • camonsertib

    Inhibits ATR kinase, disrupting DNA damage responses and promoting death of susceptible cancer cells.

    Phase 1, Small molecule, advanced solid tumor, adult advanced solid tumor

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials6
  • Funding rounds and grants1
  • Signals1
  • Similar companies6

Intelligence